Stock Market Reviews

ACXP (Acurx Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on ACXP (Acurx Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
  Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Health~Holland has awarded another grant of approximately $375,000 USD to Leiden University Medical Center (LUMC) and, through a three-party Consortium Agreement, Acurx Pharmaceuticals. The grant will fund this innovative research project entitled: POLSTOP4MDRO – Assessing conservat
  Nov 18, 2025 - $ACXP
• New to The Street Airs Landmark Show #700 Today at 6:30 PM ET on Bloomberg Television
  Featured companies include Lionscrest Advisors, DataVault AI (NASDAQ:DVLT), Pudgy Penguins (PENGU)), Peer To Peer Network (OTC:PTOP), and Acurx Pharmaceuticals (NASDAQ:ACXP). NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 /New to The Street, ...
  Nov 15, 2025 - $ACXP
• Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
  Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.
  Nov 12, 2025 - $ACXP
• Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
  Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections announced the publication of results from its scientific collaboration with Leiden University Medical Center (LUMC) demonstrating structural biology research that reveals for the first time a DNA pol IIIC inhibitor, ibezapolstat, bound to its target. The publication is entitled: A unique inhi
  Nov 10, 2025 - $ACXP
• Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
  Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today that a presentation was given by Michael Silverman, MD, FACP, Acurx's Medical Director, and Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, Principal Investigator for microbiology and microbiome aspects of the ibezapolstat clinical trial
  Oct 28, 2025 - $ACXP
• Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
  Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 am ET before the U.S. financial markets open.
  Oct 27, 2025 - $ACXP
• New to The Street to Broadcast Nationwide on Bloomberg TV Tonight at 6:30 PM EST Featuring Roadzen, Spartan Equipment, XION, Metaterra, and YY Group
  The show broadcasts as sponsored programming with featured commercials by Laser Photonics (NASDAQ:LASE), PetVivo (OTCQB:PETV), Aeries Technology (NASDAQ:AERT), Acurx Pharmaceuticals (NASDAQ:ACXP), and DataVault Holdings (NASDAQ:DVLT). NEW YORK CITY, ...
  Oct 25, 2025 - $ACXP
• New to The Street Show #694 to Broadcast Tonight at 6:30 PM EST as Sponsored Programming on Bloomberg TV Featuring Stardust Power (NASDAQ:SDST), Spartan Equipment, Roadzen (NASDAQ:RDZN), Aeries Technology (NASDAQ:AERT), and XION
  NEW YORK CITY, NY / ACCESS Newswire / October 18, 2025 /New to The Street, one of the nation's longest-running business television brands airing as sponsored programming on Bloomberg Television (6:30 PM EST) and Fox Business, announces the broadcast ...
  Oct 18, 2025 - $ACXP
• New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group
  The show is sponsored programming with commercials featuring LASE Technologies ($LASE), PetVivo ($PETV), Acurx Pharmaceuticals ($ACXP), Synergy CHC ($SNYR), and NewsOut - the video press release company. NEW YORK CITY, NY / ACCESS Newswire / October ...
  Oct 11, 2025 - $ACXP
• Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
  NEW YORK CITY, NEW YORK / ACCESS Newswire / October 10, 2025 /New to The Street, one of the nation's longest-running business television brands airing as sponsored programming on Fox Business and Bloomberg, announces its upcoming "Meet the Companies" ...
  Oct 10, 2025 - $ACXP